Compare · NVST vs RMD
NVST vs RMD
Side-by-side comparison of Envista Holdings Corporation (NVST) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVST and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.07B, about 9.0x NVST ($3.77B).
- Over the past year, NVST is up 14.7% and RMD is down 10.8% - NVST leads by 25.5 points.
- RMD has been more active in the news (9 items in the past 4 weeks vs 2 for NVST).
- Both have 25 recent analyst ratings on file.
- Company
- Envista Holdings Corporation
- ResMed Inc.
- Price
- $22.91-2.51%
- $239.08-1.35%
- Market cap
- $3.77B
- $34.07B
- 1M return
- -3.27%
- +4.60%
- 1Y return
- +14.70%
- -10.84%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2019
- News (4w)
- 2
- 9
- Recent ratings
- 25
- 25
Envista Holdings Corporation
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, and markets dental products in the United States and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Logon, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Ormco, Insignia, AOA, and Spark brands. This segment also offers software packages used for the treatment planning of dental implants and prosthetics. The company's Equipment & Consumables segment develops, manufactures, and markets dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization/magnification systems; handpieces and associated consumables; treatment units and other dental practice equipment; endodontic systems and related consumables; and restorative materials and instruments, rotary burs, impression materials, bonding agents and cements, and infection prevention products. This segment offers its products under the Dexis, Gendex, i-CAT, KaVo, Kerr, Metrex, Sybron Endo, Total Care, and Pentron brands to dental offices, clinics, and hospitals. The company was incorporated in 2018 and is headquartered in Brea, California.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest NVST
- Envista downgraded by Robert W. Baird with a new price target
- Envista Schedules Third Quarter 2026 Earnings Call
- Envista Holdings Corporation filed SEC Form 8-K: Regulation FD Disclosure
- Envista Announces Participation in Baird 2026 Global Healthcare Conference
- Envista upgraded by Analyst with a new price target
- President, Orthodontics Acurio Veronica covered exercise/tax liability with 7,710 shares, decreasing direct ownership by 14% to 48,806 units (SEC Form 4) (tax withholding)
- President, Diagnostics Befidi Robert covered exercise/tax liability with 5,147 shares, decreasing direct ownership by 10% to 45,785 units (SEC Form 4) (withholding tax)
- Chief Financial Officer Hammes Eric D. covered exercise/tax liability with 10,885 shares, decreasing direct ownership by 10% to 99,913 units (SEC Form 4) (tax liability)
- President, Nobel Biocare Nilsson Stefan covered exercise/tax liability with 804 shares, decreasing direct ownership by 1% to 61,560 units (SEC Form 4) (withholding tax)
- SVP, Strategy & Bus. Dev. Reis Mischa sold $220,000 worth of shares (8,000 units at $27.50) as part of a pre-agreed trading plan, decreasing direct ownership by 23% to 27,321 units (SEC Form 4)
Latest RMD
- SEC Form 4 filed by ResMed Inc.
- SEC Form DEFA14A filed by ResMed Inc.
- SEC Form DEF 14A filed by ResMed Inc.
- Amendment: SEC Form 4 filed by Chairman and CEO Farrell Michael J.
- Chief Product Officer Leong Justin was granted 6,461 units of ResMed Common Stock, increasing direct ownership by 22% to 35,489 units (SEC Form 4)
- Global General Counsel Rider Michael J was granted 3,230 units of ResMed Common Stock, increasing direct ownership by 34% to 12,718 units (SEC Form 4)
- Chairman and CEO Farrell Michael J. was granted 13,547 units of ResMed Common Stock, increasing direct ownership by 3% to 479,803 units (SEC Form 4)
- Chief Financial Officer Bloomer Aaron was granted 9,072 units of ResMed Common Stock (SEC Form 4)
- Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
- ResMed upgraded by RBC Capital Mkts with a new price target